BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $136,488,607 | +23.4% | 1,646,822 | +323.0% | 0.03% | +13.8% |
| Q3 2022 | $110,565,460 | -15.6% | 389,315 | +3.0% | 0.03% | -14.7% |
| Q2 2022 | $130,972,031 | -17.3% | 377,833 | +3.4% | 0.03% | -2.9% |
| Q1 2022 | $158,309,464 | -16.7% | 365,577 | -0.5% | 0.04% | -10.3% |
| Q4 2021 | $190,000,000 | +9.9% | 367,264 | +2.9% | 0.04% | +2.6% |
| Q3 2021 | $172,950,000 | +12.5% | 356,914 | +4.5% | 0.04% | +15.2% |
| Q2 2021 | $153,757,000 | +19.5% | 341,486 | +1.4% | 0.03% | +13.8% |
| Q1 2021 | $128,644,000 | +17.2% | 336,826 | -2.6% | 0.03% | +11.5% |
| Q4 2020 | $109,774,000 | +32.0% | 345,692 | +3.0% | 0.03% | +18.2% |
| Q3 2020 | $83,167,000 | -16.4% | 335,718 | -10.9% | 0.02% | -24.1% |
| Q2 2020 | $99,483,000 | +19.8% | 376,728 | -14.0% | 0.03% | -3.3% |
| Q1 2020 | $83,069,000 | -13.4% | 438,082 | +0.3% | 0.03% | +11.1% |
| Q4 2019 | $95,918,000 | +1.1% | 436,965 | -9.9% | 0.03% | -6.9% |
| Q3 2019 | $94,869,000 | -6.1% | 484,839 | 0.0% | 0.03% | -6.5% |
| Q2 2019 | $101,084,000 | +5.0% | 484,839 | 0.0% | 0.03% | 0.0% |
| Q1 2019 | $96,265,000 | +35.6% | 484,839 | -1.2% | 0.03% | +19.2% |
| Q4 2018 | $70,995,000 | -28.2% | 490,571 | +1.3% | 0.03% | -18.8% |
| Q3 2018 | $98,880,000 | +38.0% | 484,443 | 0.0% | 0.03% | +28.0% |
| Q2 2018 | $71,674,000 | -2.0% | 484,443 | 0.0% | 0.02% | -3.8% |
| Q1 2018 | $73,171,000 | +14.5% | 484,443 | -1.8% | 0.03% | +13.0% |
| Q4 2017 | $63,912,000 | -3.9% | 493,343 | -10.3% | 0.02% | -8.0% |
| Q3 2017 | $66,482,000 | +2.9% | 549,941 | 0.0% | 0.02% | -3.8% |
| Q2 2017 | $64,618,000 | +20.2% | 549,941 | +4.0% | 0.03% | +18.2% |
| Q1 2017 | $53,759,000 | +8.5% | 528,859 | +9.8% | 0.02% | 0.0% |
| Q4 2016 | $49,542,000 | +0.7% | 481,788 | +2.4% | 0.02% | -4.3% |
| Q3 2016 | $49,201,000 | -7.3% | 470,447 | 0.0% | 0.02% | -8.0% |
| Q2 2016 | $53,052,000 | +22.8% | 470,447 | +2.9% | 0.02% | +19.0% |
| Q1 2016 | $43,193,000 | +5.0% | 456,971 | 0.0% | 0.02% | +5.0% |
| Q4 2015 | $41,127,000 | -2.7% | 456,971 | 0.0% | 0.02% | -9.1% |
| Q3 2015 | $42,252,000 | +25.4% | 456,971 | +33.6% | 0.02% | +29.4% |
| Q2 2015 | $33,685,000 | -1.8% | 342,081 | 0.0% | 0.02% | 0.0% |
| Q1 2015 | $34,307,000 | +5.3% | 342,081 | -2.9% | 0.02% | 0.0% |
| Q4 2014 | $32,565,000 | – | 352,437 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |